Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.
Weintraub
Daniel
D
Department of Psychiatry, University of Pennsylvania, 3535 Market St., Rm. 3003, Philadelphia, PA 19104, USA. weintrau@mail.med.upenn.edu
Hurtig
Howard I
HI
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000068180:Aripiprazole; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic / Q000706:statistics & numerical data; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D020961:Lewy Body Disease / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D010300:Parkinson Disease / Q000175:diagnosis* / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000175:diagnosis* / Q000188:drug therapy*; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D003987:Dibenzothiazepines; D010879:Piperazines; D015363:Quinolones; D000069348:Quetiapine Fumarate; D000068180:Aripiprazole; D003024:Clozapine